Sippican Capital Advisors Has $2.25 Million Stock Holdings in Pfizer Inc. $PFE

Sippican Capital Advisors boosted its position in Pfizer Inc. (NYSE:PFE) by 37.4% during the second quarter, Holdings Channel reports. The institutional investor owned 92,912 shares of the biopharmaceutical company’s stock after purchasing an additional 25,285 shares during the quarter. Pfizer comprises approximately 1.6% of Sippican Capital Advisors’ portfolio, making the stock its 20th largest holding. Sippican Capital Advisors’ holdings in Pfizer were worth $2,252,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter worth approximately $28,000. Horizon Financial Services LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $24.81 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a fifty day simple moving average of $24.86 and a 200 day simple moving average of $24.13. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The company has a market capitalization of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.